Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test vs. needle biopsy: can a simple draw detect lung cancer mutations?

NCT ID NCT03265496

Knowledge-focused Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a blood test (liquid biopsy) could find EGFR gene mutations in lung cancer patients as accurately as a standard tumor biopsy. Researchers planned to enroll 21 patients with advanced lung cancer who had not yet received treatment. The study was terminated early, so the findings are limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could show that a simple blood test (liquid biopsy) can reliably detect EGFR mutations, reducing the need for invasive tumor biopsies.
What could go wrong
The study was terminated early with only 21 participants, so results are limited. The approach may not be accurate enough to replace standard tissue biopsy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

21 people

The number who actually took part.

Started

Jul 2016

Finished

Apr 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At least 18 years * Metastatic lung carcinoma * With: - EGFR gene mutation * Or at least 2 predictive factors of addictive mutation (Women, non smocking or cessation \> 3 years, Asiatic, lung adenocarcinoma) * Eligible for 1st line treatment * Performance status ≤ 3 * Available tumor sample or tumor reachable for biopsy * With informed and signed consent * Affiliation to the National Social Security System Exclusion Criteria: * Previous radiotherapy treatment in months preceding initials samples * Pregnant or breastfeeding women * Patient not able to give consent or unwilling to provide consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic lung carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

Contacts and locations

Locations

  • CHRU Lille

    Lille, 59037, France

  • Centre Oscar Lambret

    Lille, 59020, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.